KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$408.0 million.

  • CRISPR Therapeutics AG's Net Income towards Common Stockholders fell 23.82% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 96.03%. This contributed to the annual value of -$408.0 million for FY2024, which is 121.25% down from last year.
  • As of FY2024, CRISPR Therapeutics AG's Net Income towards Common Stockholders stood at -$408.0 million, which was down 121.25% from -$184.4 million recorded in FY2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Net Income towards Common Stockholders peaked at $377.7 million during FY2021, and registered a low of -$652.5 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$415.0 million, with a median of -$408.0 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 633.21% in 2020, then surged by 205.94% in 2021.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Net Income towards Common Stockholders stood at -$356.5 million in 2020, then surged by 205.94% to $377.7 million in 2021, then slumped by 272.78% to -$652.5 million in 2022, then soared by 71.74% to -$184.4 million in 2023, then tumbled by 121.25% to -$408.0 million in 2024.